obj pain patch , page-12

1S1,
Compound used for the patches has not been named, therefore no obligation to publish anything as yet.

It addresses musculoskeletal pain, excactly fitting the target area of Tripeptofen.
Naltrexone previously tested by OBJ does not fit that category, in fact no compound tested within the analgesic market fits this description as well as Tripeptofen does.


It would explain some of the wording within PNO announcements lately of product development and in particular license negotiations .
That wording made me very curious in the last shareholder update of PNO.
OBJ might be the one paying for this.
Naturally, this would not be disclosed at this point in time as an innovative pain relief patch would be a possible blockbuster and this needs to be protected until product is ready for commercialisation.
Until then, all we can do is connect the dots, which have a way of jumping right at me here at the moment.